Quantification With Lutetium-177 on Cadmium-Zinc-Telluride Camera 3D

Launched by CENTRAL HOSPITAL, NANCY, FRANCE · Jan 14, 2025

Keywords

ClinConnect Summary

This clinical trial, titled "Quantification With Lutetium-177 on Cadmium-Zinc-Telluride Camera 3D," is focused on improving how we measure and analyze imaging results in patients with prostate cancer who have received a specific treatment called lutetium vipivotide tetraxetan. The main goal of the study is to see if we can accurately gather and analyze images using different energy settings from a special camera, which might help doctors get better information about the cancer.

To be eligible for this study, participants must be individuals who have undergone at least one treatment with lutetium vipivotide tetraxetan and have imaging data available for review. The study is not currently recruiting participants, and it will look back at previously collected data, so no new treatments will be given as part of this trial. If you have concerns about your data being used, it's important to note that patients who object to the use of their information will not be included in the study. Overall, this research aims to enhance the way cancer imaging is done, which could lead to better care for patients in the future.

Gender

ALL

Eligibility criteria

• It is a retrospective study and the criteria to collect the imaging are:
• Inclusion Criteria:
• • Patients treated by at least one cure of lutetium vipivotide tetraxetan with imaging
• Exclusion Criteria:
• • Patient having sent an objection to the use of their data